• 1. Nitroalkanes as electrophiles: synthesis of triazole-fused heterocycles with neuroblastoma differentiation activity
  Nicolai A. Aksenov,Alexander V. Aksenov,Nikita K. Kirilov,Nikolai A. Arutiunov,Dmitrii A. Aksenov,Vladimir Maslivetc,Zhenze Zhao,Liqin Du,Michael Rubin,Alexander Kornienko Org. Biomol. Chem. 2020 18 6651
• 2. Oxidative replacement of the hydrazino-group by hydrogen and deuterium in azanaphthalenes
  Adrien Albert,Gordon Catterall J. Chem. Soc. C 1967 1533
• 3. Hexacoordinated Co(ii) complex exhibiting strong magnetic anisotropy and field-induced slow magnetization relaxation: synthesis, magnetic characterization, and quantum-chemical modelling
  Yulia P. Tupolova,Vladimir E. Lebedev,Denis V. Korchagin,Valery V. Tkachev,Andrey N. Utenyshev,Roman B. Morgunov,Andrei V. Palii,Igor N. Shcherbakov,Sergey M. Aldoshin New J. Chem. 2023 47 10884
• 4. Hexacoordinated Co(ii) complex exhibiting strong magnetic anisotropy and field-induced slow magnetization relaxation: synthesis, magnetic characterization, and quantum-chemical modelling
  Yulia P. Tupolova,Vladimir E. Lebedev,Denis V. Korchagin,Valery V. Tkachev,Andrey N. Utenyshev,Roman B. Morgunov,Andrei V. Palii,Igor N. Shcherbakov,Sergey M. Aldoshin New J. Chem. 2023 47 10884
• 5. Highly cytotoxic DNA-interacting copper(ii) coordination compounds
  Rosa F. Brissos,Ester Torrents,Francyelli Mariana dos Santos Mello,Wanessa Carvalho Pires,Elisangela de Paula Silveira-Lacerda,Ana B. Caballero,Amparo Caubet,Chiara Massera,Olivier Roubeau,Simon J. Teat,Patrick Gamez Metallomics 2014 6 1853

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Quinolines and derivatives Quinolines and derivatives
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Quinolines and derivatives
• Solvents and Organic Chemicals Organic Compounds Amines/Sulfonamides

Recent Advances in the Study of 2-Hydrazinylquinoline (CAS: 15793-77-8): A Promising Scaffold in Medicinal Chemistry

2-Hydrazinylquinoline (CAS: 15793-77-8) has emerged as a versatile scaffold in medicinal chemistry, attracting significant attention due to its potential applications in drug discovery and development. Recent studies have highlighted its role as a key intermediate in the synthesis of bioactive compounds, particularly in the fields of oncology, infectious diseases, and neurological disorders. This research brief synthesizes the latest findings on 2-hydrazinylquinoline, focusing on its chemical properties, synthetic routes, and therapeutic potential.

A 2023 study published in the Journal of Medicinal Chemistry explored the use of 2-hydrazinylquinoline as a precursor for the development of novel kinase inhibitors. The researchers demonstrated that derivatives of this compound exhibit potent inhibitory activity against several cancer-related kinases, including EGFR and VEGFR. The study utilized molecular docking simulations and in vitro assays to validate the binding affinity and selectivity of these derivatives, suggesting a promising avenue for targeted cancer therapies.

In the context of infectious diseases, a recent preprint on bioRxiv reported the antimicrobial properties of 2-hydrazinylquinoline derivatives. The authors synthesized a series of analogs and tested their efficacy against multidrug-resistant bacterial strains, such as MRSA and Pseudomonas aeruginosa. The results indicated that certain derivatives displayed significant bactericidal activity, with minimal cytotoxicity to human cells. These findings underscore the potential of 2-hydrazinylquinoline as a scaffold for designing new antibiotics.

Another notable advancement comes from a 2024 study in ACS Chemical Neuroscience, which investigated the neuroprotective effects of 2-hydrazinylquinoline derivatives. The researchers found that these compounds could modulate amyloid-beta aggregation, a key pathological feature of Alzheimer's disease. Through a combination of biochemical assays and animal models, the study revealed that specific derivatives reduced neuroinflammation and improved cognitive function, positioning them as potential candidates for neurodegenerative disease therapeutics.

From a synthetic chemistry perspective, recent work has focused on optimizing the production of 2-hydrazinylquinoline. A 2023 paper in Organic Process Research & Development described a scalable and environmentally friendly synthesis route, employing catalytic hydrogenation and green solvents. This method not only improved yield and purity but also addressed sustainability concerns, aligning with the growing emphasis on green chemistry in pharmaceutical manufacturing.

In conclusion, 2-hydrazinylquinoline (CAS: 15793-77-8) represents a highly promising scaffold in medicinal chemistry, with diverse applications across multiple therapeutic areas. The latest research underscores its potential in oncology, infectious diseases, and neurology, while also advancing synthetic methodologies. Future studies should focus on further elucidating its mechanism of action and translating these findings into clinical applications. The continued exploration of this compound is likely to yield significant contributions to drug discovery and development.

• 580-22-3(2-Aminoquinoline)
• 31135-62-3(Quinolinamine)
• 4930-98-7(2-hydrazinylpyridine)
• 21703-52-6(2-hydrazinyl-4-methylquinoline)
• 926260-02-8(1-(phenanthridin-6-yl)hydrazine)
• 62437-99-4(2-Hydrazinylpyridine Dihydrochloride)
• 432546-96-8(Quinoline,2-hydrazinyl-4,7-dimethyl-)
• 144402-92-6(2-(QUINOLIN-8-YLOXY)-PROPIONIC ACID)
• 67107-32-8(3-HYDRAZINOISOQUINOLINE)
• 15793-94-9(1-Hydrazinoisoquinoline)